The firms will work together to create a bispecific antibody with two anti-cancer payloads and evaluate its therapeutic potential.
Platforms using natural language processing are showing promise in scanning patients' records for biomarkers and other enrollment criteria for clinical trials.
The firm will pause development of lunresertib and camonsertib while focusing on development of two newer programs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback